BSE · 530233
Auro Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹9 Cr with net profit ₹1 Cr — a 11.97% net margin, versus 9.87% the period before.
Shareholding
As of 2026-06-30
- Promoter52.41%
- Public47.59%
- DII0.01%
8,315 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #15 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,48,147 Cr | 83.29 | 14.8 | 15.32% | 26.05% |
| Neuland Laboratories Ltd. | ₹30,567 Cr | 61.41 | 16.32 | 19.42% | 20.99% |
| Acutaas Chemicals Limited | ₹28,106 Cr | 72.78 | 17 | 21.54% | 26.42% |
| Jubilant Pharmova Ltd. | ₹16,193 Cr | 41.73 | 2.28 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd. | ₹4,336 Cr | 42.36 | 5.52 | 12.98% | 11.41% |
| Aarti Drugs Ltd. | ₹3,943 Cr | 20.46 | 2.55 | 12.58% | 7.14% |
| Hikal Limited | ₹2,775 Cr | 65.43 | 2.32 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,273 Cr | 49.86 | 9.25 | 16.95% | 11.11% |
| NGL Fine Chem Limited | ₹1,660 Cr | 29.03 | 5.04 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,400 Cr | 25.57 | 3.44 | 17.67% | 11.68% |
| Auro Laboratories Ltd.(this company) | ₹158 Cr | 85.75 | 3.67 | 4.47% | 8.42% |
AI analysis
AI-generated · google/gemini-2.5-flashAuro Laboratories Ltd. is listed on the Indian markets with a market capitalization of Rs 152 Cr. The company reported revenue of Rs 20.05 Cr and a profit margin of 8.42% for the year ending March 2025. Its book value stands at Rs 68.95.
Positives
- +Promoter holding is 52.405%, indicating significant control by the founders.
- +The company has no pledged promoter shares, with promoter pledge at 0%.
Negatives
- −The Price-to-Earnings (PE) ratio is 82.56, which is relatively high.
- −The company reported a net loss of Rs -0.11 Cr for the quarter ending June 2025.
- −No dividend yield has been reported for the company (0%).
- −No quarterly results have been disclosed since September 2025.
- −No annual revenue growth figure is available.
Financial performance
For the fiscal year ending March 2025, Auro Laboratories Ltd. generated revenue of Rs 20.05 Cr. The company's net profit for the same period was Rs 1.8387 Cr, resulting in an EPS of Rs 2.95. Quarterly results show revenue of Rs 2.77 Cr and a net loss of Rs -0.11 Cr for June 2025, followed by revenue of Rs 8.84 Cr and net profit of Rs 0.72 Cr for September 2025.
Profitability & returns
Auro Laboratories Ltd. achieved a profit margin of 8.42% for the year ending March 2025. The company's Return on Capital Employed (ROCE) is 7.3065%, while its Return on Equity (ROE) is 447.2%. The EPS for the period ending March 2025 was Rs 2.95.
Balance sheet
The company's debt-to-equity ratio is 0.81. Auro Laboratories Ltd. has a book value of Rs 68.95 per share. The market capitalization of the company is Rs 152 Cr.
Ownership & pledges
As of June 2026, the promoter holding in Auro Laboratories Ltd. is 52.405%. The company has no pledged promoter shares. The total number of shareholders was 8315 as of June 2026.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.